{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:31:23Z","timestamp":1793709083566,"version":"4.6.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate whether Staphylococcus aureus bloodstream infection (SAB) patients at high risk for complications or relapse benefit from combination therapy with adjunctive rifampicin or fosfomycin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this post hoc analysis, SAB patients with native valve infective endocarditis, osteoarticular infections or implanted foreign devices were included. The co-primary endpoints were all-cause 90\u2009day mortality and death or SAB-related late complications within 180\u2009days. To overcome treatment selection bias and account for its time dependence, inverse probability of treatment weights were calculated and included in marginal structural Cox proportional hazard models (MSCMs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 578 patients were included in the analysis, of which 313 (54%) received combination therapy with either rifampicin (n\u2009=\u2009242) or fosfomycin (n\u2009=\u200958). In the multivariable MSCM, combination therapy was associated with a better outcome, that is, a lower rate of death or SAB-related late complications within 180\u2009days (HR 0.65, 95% CI 0.46\u20130.92). This beneficial effect was primarily seen in patients with implanted foreign devices, in which combination therapy was associated with a lower rate of death or SAB-related late complications within 180\u2009days (HR 0.53, 95% CI 0.35\u20130.79) and a lower 90\u2009day mortality (HR 0.57, 95% CI 0.36\u20130.91). Upon agent-specific stratification, we found no significant differences in outcomes between combination therapy containing rifampicin and fosfomycin; however, the number of patients in most subgroups was not large enough to draw firm conclusions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with implanted foreign devices, combination therapy was associated with a better long-term outcome. Larger prospective studies are needed to validate these findings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa144","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T20:09:35Z","timestamp":1585166975000},"source":"Crossref","is-referenced-by-count":10,"title":["Combination therapy with rifampicin or fosfomycin in patients with Staphylococcus aureus bloodstream infection at high risk for complications or relapse: results of a large prospective observational cohort"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-7080","authenticated-orcid":false,"given":"Siegbert","family":"Rieg","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine II, Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2375-1889","authenticated-orcid":false,"given":"Angela","family":"Ernst","sequence":"first","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine, University of Cologne, 50924 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Peyerl-Hoffmann","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine II, Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insa","family":"Joost","sequence":"first","affiliation":[{"name":"Institute of Medical Microbiology and Hospital Hygiene, Heinrich-Heine-University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Camp","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine II, Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hellmich","sequence":"first","affiliation":[{"name":"Institute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine, University of Cologne, 50924 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried V","family":"Kern","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine II, Medical Center \u2013 University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim J","family":"Kaasch","sequence":"first","affiliation":[{"name":"Institute of Medical Microbiology and Hospital Hygiene, Heinrich-Heine-University D\u00fcsseldorf, 40225 D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Seifert","sequence":"first","affiliation":[{"name":"Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, 50937 Cologne, Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"2020050506074768700_dkaa144-B1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/QCO.0b013e32833bcc8a","article-title":"Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges","volume":"23","author":"Kern","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"2020050506074768700_dkaa144-B2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1473-3099(10)70285-1","article-title":"Clinical management of Staphylococcus aureus bacteraemia","volume":"11","author":"Thwaites","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2020050506074768700_dkaa144-B3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020050506074768700_dkaa144-B4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jinf.2018.08.015","article-title":"Survival following Staphylococcus aureus bloodstream infection: a prospective multinational cohort study assessing the impact of place of care","volume":"77","author":"Nambiar","year":"2018","journal-title":"J Infect"},{"key":"2020050506074768700_dkaa144-B5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2020050506074768700_dkaa144-B6","doi-asserted-by":"crossref","first-page":"e0122824","DOI":"10.1371\/journal.pone.0122824","article-title":"Improved outcome with early rifampicin combination treatment in methicillin-sensitive Staphylococcus aureus bacteraemia with a deep infection focus - a retrospective cohort study","volume":"10","author":"Forsblom","year":"2015","journal-title":"PLoS One"},{"key":"2020050506074768700_dkaa144-B7","doi-asserted-by":"crossref","first-page":"406.e1","DOI":"10.1016\/j.cmi.2016.08.026","article-title":"Combination antimicrobial therapy in patients with Staphylococcus aureus bacteraemia\u2014a post hoc analysis in 964 prospectively evaluated patients","volume":"23","author":"Rieg","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2020050506074768700_dkaa144-B8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"2020050506074768700_dkaa144-B9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0140-6736(18)31555-1","article-title":"Rifampicin in treating S aureus bacteraemia","volume":"392","author":"Rieg","year":"2018","journal-title":"Lancet"},{"key":"2020050506074768700_dkaa144-B10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/313753","article-title":"Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis","volume":"30","author":"Li","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020050506074768700_dkaa144-B11","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2020050506074768700_dkaa144-B12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/01621459.1999.10474168","article-title":"Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome","volume":"94","author":"Robins","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2020050506074768700_dkaa144-B13","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/cid\/ciy1144","article-title":"Clinical practice variation among adult infectious disease physicians in the management of Staphylococcus aureus bacteremia","volume":"69","author":"Liu","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020050506074768700_dkaa144-B14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0140-6736(17)33294-4","article-title":"Rifampicin for Staphylococcus aureus bacteraemia: give it ARREST","volume":"391","author":"Holland","year":"2018","journal-title":"Lancet"},{"key":"2020050506074768700_dkaa144-B15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2018.13155","article-title":"Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with staphylococcal bacteremia: a randomized clinical trial","volume":"320","author":"Holland","year":"2018","journal-title":"JAMA"},{"key":"2020050506074768700_dkaa144-B16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciy774","article-title":"Considerations for clinical trials of Staphylococcus aureus bloodstream infection in adults","volume":"68","author":"Holland","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020050506074768700_dkaa144-B17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2020050506074768700_dkaa144-B18","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM)","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"2020050506074768700_dkaa144-B19","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/424506","article-title":"A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection","volume":"39","author":"Schrenzel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020050506074768700_dkaa144-B20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eimc.2018.05.009","article-title":"Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocci","volume":"37","author":"Coronado-Alvarez","year":"2019","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2020050506074768700_dkaa144-B21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin\u2014back to the future. Systematic review and meta-analysis of the clinical literature","volume":"23","author":"Grabein","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2020050506074768700_dkaa144-B22","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1128\/AAC.06449-11","article-title":"High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis","volume":"56","author":"Miro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020050506074768700_dkaa144-B23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cmi.2018.01.010","article-title":"Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial","volume":"24","author":"Pericas","year":"2018","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkaa144\/33166265\/dkaa144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkaa144\/33166265\/dkaa144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T10:08:24Z","timestamp":1588673304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dkaa144\/5827555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa144","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]},"article-number":"dkaa144"}}